PRISM BioLab announces that we have received a Notice of Allowance for a patent on PepMetics® technology library compounds in the United States. For more details, please click here (Japanese language PDF).

PRISM BioLab announces that Eisai Co., Ltd. will present preclinical research results for E7386, co-created by PRISM BioLab and Eisai, in combination with lenvatinib mesylate, at the American Association for Cancer Research (AACR) Annual Meeting 2026 from April 17 to 22, 2026. The abstract of the study has been disclosed. For more details, please click...

PRISM BioLab and Receptor.AI today announced that they have entered into a drug discovery collaboration agreement to develop an integrated, AI-navigated, physics-guided platform for the discovery of orally available small molecules targeting intracellular protein–protein interactions (PPIs), membrane proteins, and complex receptor systems. For more details, please click here.

PRISM BioLab announces that a paper reporting the results of a domestic Phase I clinical trial on E7386, jointly created with Eisai Co., Ltd. has been published in the ESMO OPEN, the open access medical journal issued by the European Society for Medical Oncology (ESMO). For more details, please click here.

We would like to inform you that PRISM BioLab will relocate our Tokyo office to the address below, effective January 19, 2026. Please note that our main phone number will remain unchanged. Relocation Date: January 19, 2026 New Address: Nihonbashi Life Science Building 2, Room 401 3-11-5 Nihonbashi-Honcho, Chuo-ku Tokyo 103-0023, Japan Phone: +81-466-53-8383 (Main)...

PRISM BioLab and Talus Bioscience, Inc. are pleased to announce that we have entered into a joint research agreement to discover novel inhibitors targeting transcription factors and protein-protein interactions (PPIs). For more details, please click here.

PRISM BioLab was granted a new patent covering a novel class of bicyclic PepMetics® compounds on 17th November, 2025. For more details, please click here (Japanese language PDF).

Financial Results for the Fiscal Year Ended September 2025 (Japanese GAAP) (Non-Consolidated)

PRISM BioLab is pleased to announce that we have achieved the initial milestone in our drug discovery collaboration with Ono Pharmaceutical Co., Ltd. and will receive an upfront payment. For more details, please click here.

PRISM BioLab is pleased to announce that a Phase I clinical study on drug-drug interactions of PRI-724/OP-724 (generic name: foscelbinib), which has been licensed to Ohara Pharmaceutical Co., Ltd., has been initiated. For more details, please click here (Japanese language PDF).